Company: GIFLF
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001104659-25-071915
Chunk: 0

Company: Grifols SA
Filing Date: 2025-07-30
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File No. 001-35193

Grifols, S.A.

(Translation of registrant’s name into English)

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive
office)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.

| Form 20-F x |     | Form 40-F 
 ¨         |

<div align='center'>Grifols, S.A.

TABLE OF CONTENTS</div>

| Item 
 1.   
 2.   | Press release, dated July 29, 2024                                                              
 Results presentation, dated July 29, 2024                                                       |     | Sequential Page Number 
                      3 
                      7 |
|:-----|:------------------------------------------------------------------------------------------------|:----|-----------------------:|
| 3.   | Condensed Consolidated Interim Financial Statements for the six-month period ended 30 June 2025 |     |                     47 |

Half-Year 2025 Results

Grifols increases its revenues by 7% to EUR 3,677m and boosts its net profit to EUR 177m

| · | Revenues reached EUR 3,677 million                                                   
 up 7.0% at constant currency (cc1), driven by the solid performance of the Biopharma 
 segment, which recorded 8.2% growth at constant currency                             |

| · | Adjusted EBITDA increased to EUR 876                         
 million, which represents a 12.7% cc growth and 23.8% margin |

| · | Group net profit increased to EUR                       
 177 million, close to 4x the figure reported in H1 2024 |

| · | Free cash flow2 before                       
 M&A improved by EUR 182 million year on year |

| · | Leverage ratio3 decreased                            
 to 4.2x, with liquidity standing